The ability to generate spiral ganglion neurons (SGNs) from stem cells is a necessary prerequisite for development of cell-replacement therapies for sensorineural hearing loss. We present a protocol that directs human embryonic stem cells (hESCs) toward a purified population of otic neuronal progenitors (ONPs) and SGN-like cells. Between 82% and 95% of these cells express SGN molecular markers, they preferentially extend neurites to the cochlear nucleus rather than nonauditory nuclei, and they generate action potentials. The protocol follows an in vitro stepwise recapitulation of developmental events inherent to normal differentiation of hESCs into SGNs, resulting in efficient sequential generation of nonneuronal ectoderm, preplacodal ectoderm, early prosensory ONPs, late ONPs, and cells with cellular and molecular characteristics of human SGNs. We thus describe the sequential signaling pathways that generate the early and later lineage species in the human SGN lineage, thereby better describing key developmental processes. The results indicate that our protocol generates cells that closely replicate the phenotypic characteristics of human SGNs, advancing the process of guiding hESCs to states serving inner-ear cell-replacement thera- 
INTRODUCTION
Approximately 360 million people have disabling hearing losses [1], a number likely to grow due to increasing noise pollution and human longevity. The most common impairment is sensorineural hearing loss (SNHL). Stem-cell replacement of spiral ganglion neurons (SGNs) may effectively treat SNHL, motivating efforts for differentiating pluripotent stem cells (PSCs) into glutamatergic sensory neurons similar to SGNs [2] [3] [4] [5] . Clinical translation of these findings faces hurdles, including developing efficient protocols, accurate reproduction of phenotypic characteristics of human SGNs, delivery and creation of supportive niches, confirmation of normal physiology of SGNs and ascending neural stages, and ultimately, restoration of hearing. This paper primarily addresses the first two hurdles and presents some SGN-level physiological findings.
A simplified model of SGN lineage indicates that PSCs first give rise to nonneuronal ectoderm (NNE), which develops into preplacodal ectoderm (PPE) [6] . PPE then becomes cranial placodes, including the otic placode, which contains SGN precursors [6] . Although developmental pathways governing commitment of precursor cells to human SGNs are not completely understood, substantial insight has been provided by studies of chick, Xenopus, and rodent nervous systems and recent studies of human embryonic stem cells (hESCs) [7] . Inhibition of TGF-b signaling in cultured human and mouse ESCs increases efficiency of ectoderm generation [8, 9] , which is biased to NNE fates by bone morphogenetic protein 4 (BMP4) signaling [10, 11] . Thus, subsequent inhibition of BMP signaling and activation of FGF pathways are essential to selectively differentiate NNE into PPE [12] [13] [14] . Wnt signaling limits lateral and posterior extents of the preplacodal region, inhibiting PPE differentiation [15] ; transient Wnt inhibition helps create a PPE lineage [16] . Subsequent combined Wnt and FGF signaling is required to generate the otic placode and suppress other epibranchial placode domains [17] [18] [19] [20] and insulin-like growth factor-1 (IGF-1) supports survival and proliferation of early otic vesicles [21] [22] [23] [24] . These observations suggest that FGF, Wnt, and IGF-1 signaling are primary inducers of the otic placode. In vivo, the otic placode invaginates into mesenchyme to form the otic vesicle. Its ventral region contains prosensory otic neuronal progenitors (ONPs) that give rise to primary sensory neurons, including SGNs. Sonic Hedgehog (SHH) is required for ventral patterning of the inner ear in mice and acts synergistically with all-trans retinoic acid (ATRA) to facilitate otic sensory neuronal differentiation [25, 26] .
We hypothesized that in vitro stepwise recapitulation of these developmental events efficiently facilitates differentiation of hESCs into SGNs. We define a protocol that efficiently generates cells that display phenotypic characteristics of SGNs and preferentially innervate the appropriate cochlear nucleus (CN) target in organotypic rat brainstem slice cocultures containing CN and ONPs. Our approach offers the advantage of discrete subprotocols, each of which can be further improved. The protocol was evaluated using multiple approaches. At key stages along its 42-63 day extent, outcomes were evaluated using immunocytochemistry, RT-PCR, and the rat ONP/CN coculture. Although not the focus of protocol development and evaluation, we also conducted physiological assessments on SGN-like cells.
MATERIALS AND METHODS
See Supporting Information for details of all procedures and reagents and Figure 1 for the schematized protocol.
Development Stage 1: Generation of NNE-Like and PPE-Like Cells
Human ESC lines H1, H7, and H9 (passages [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ; WiCell Research Institute, Madison, Wisconsin, USA, https://www.wicell.org) were cultured as previously described [27] . The step-wise processing is shown diagrammatically in Figure 1 . Prior to differentiation, hESCs were purified using an Anti-TRA-1-60 MicroBead Kit, Feeder Removal Microbeads (mouse), LS Columns, and a MidiMACS Separator (Miltenyi Biotec, Bergisch Gladbach, Germany, http://www. miltenyibiotec.com). Single-suspended cells were plated on Geltrex (ThermoFisher Scientific, Waltham, MA, USA, http://www. thermofisher.com) coated plates either in Essential 8 medium (E8, ThermoFisher Scientific, Waltham, MA, USA) or mTeSR (STEMCELL Techonologies, Cambridge, MA, USA, https://www.stemcell.com) with Rho kinase inhibitor Y27632 (10 mM) for 48 hours at 10,000 cells cm
22
; this density minimizes differentiation toward central nervous system (CNS) neurons [8] .
Differentiation toward NNE lineage was initiated 72 hours at day 3 (D3, Fig. 1 ) after seeding by changing medium from E8 to a chemically defined medium containing N2 and B27 supplements (N2B27-CDM) [14, 28] and adding 10 ng ml 21 recombinant BMP4, 1 lM SB431542, and 10 ng ml 21 recombinant human FGF2 for 3 days. Differentiation toward PPE lineage was initiated at D6 (Fig. 1 ) by adding 2 lM IWP-2 along with dual SMAD signal inhibition [29] (1 lM SB431542 and 100 nM of LDN-193189 for 5 days). Cells were positively selected for p75 NTR and negatively selected for TRA-1-81 using "gentle" fluorescence activated cell sorting (FACS) [30] with a FACS Aria SORP 4/5-Laser. Alternatively, a MACS neural stem cell microbead kit along with the Anti-TRA-1-60 MicroBead Kit, LS Columns, and a MidiMACS Separator was used to positively select cells for p75 NTR and negatively select for TRA-1-60 [31] .
Development Stage 2: ONP Generation
After purification at day 11, cells were seeded at 25,000 cells cm 22 on 12 mm coverslips maintained in N2B27-CDM with 100 ng ml 21 human Wnt3a, 10 ng ml 21 human FGF2, and 50 ng ml
21
IGF-1 (W/F/I), initiating the "early-stage ONP" epoch (D11-D16, Fig. 1 ). The "mid-stage ONP" epoch, initiated at D16, included two additional W/F/I days followed by 3-day treatment with 500 ng ml 21 SHH, 0.5 lM ATRA, 10 ng ml 21 human FGF2, 20 ng ml
EGF, and 50 ng ml 21 IGF-1 (S/R/E/F/I) in N2B27-CDM. The "latestage ONP" epoch began at D21 with four additional days of S/R/ E/F/I treatment ( Fig. 1) . Some cells were maintained in ONP maintenance medium (ONPMM) before further sensory neuronal differentiation.
Development Stage 3: Sensory Neuronal Differentiation (SGN-Like Cells)
colocalization. Images were quantified using ImageJ. Cell viability was assessed using a 3-(4,5-dimethylthiazol-2yl)-2,5 diphenyl tetra-zolium bromide (MTT) Cell Proliferation Assay Kit [34] .
Electrophysiological Assessments
Three approaches were used to assess physiological responses of SGN-like cells: (a) calcium imaging [32] , (b) whole-cell recordings of hESC-derived neurons, using an Axopatch 200A amplifier and standard cell-clamp approaches, and (c) a voltage-sensitive dye (VSD) to noninvasively assess electrically evoked cell depolarization consistent with neuronal activity, following established protocol [35] and further outlined in the Supporting Information.
The Organotypic Rat Brainstem Slice Culture With hESC-Derived ONPs
We developed a coculture consisting of an ONP aggregate and rat CN within a brainstem slice to study directed neurite growth and connectivity. The organotypic brainstem slice protocol has been described elsewhere [36, 37] and in the Supporting Information. Brainstem slices containing the nucleus of the solitary tract (NST) near the middle olive were also cocultured as controls to evaluate the specificity of neurite extension to the CN. ONPs within a collagen gel sphere or a self-assembling peptide amphiphile bearing an IKVAV epitope (IKVAV-PA [38] ) were positioned 750 lm from the CN or NST 4 days after 
RESULTS

Evaluation of hESC-Derived SGN-Like Cells
Stage 1: hESC-Derived NNE-Like and PPE-Like Cells. Within the NNE epoch (initiated at D3), treatment duration was optimized for efficiency using immunocytochemistry for AP2a and DLX3 (NNE markers [40, 41] ). Figures 2B and 2C indicate that 3-day treatment with BMP4/FGF2 (labeled "B/F") or BMP4/ SB431542/FGF2 ("B/SB/F") sufficed for expression of AP2a and DLX3 in >90% of cells. We also evaluated possible aberrant differentiation into mesoendoderm using immunocytochemistry for Brachyury [9] . B/SB/F treatment markedly suppressed Brachyury expression compared with B/F or N2B27-CDM-only treatment (Fig. 2D ). Human ESC morphology before ( Fig. 2E(a) ) and after B/ SB/F treatment (at D1 in Fig. 2E (b) and D5 in Fig. 2E(c) ) demonstrated changes from round to spindle-like shapes (also Supporting Information Fig. 1A ). In adherent monolayer cultures, differentiation usually was initiated at the colony's outer border (white arrowheads, Fig. 2E(b) ). Figure 2F shows immunocytochemistry for DLX3, DLX5, GATA2, and AP2a (markers for NNE [42] ), indicating high conversion efficiency from undifferentiated hESCs into NNE. At D6, treatment of NNE-like cells with dual SMAD signal inhibition (LDN193189 or Noggin 1 SB431542), FGF2, and Wnt antagonist IWP-2 to differentiate into PPE lineage (Figs. (1 and 2)G) . We determined the effectiveness of PPE lineage induction by quantitative immunocytochemistry for EYA1 and SIX4, known PPE markers [40, 41] , after 3, 5, 7, and 14 days of treatment. NNE-like cells were also cultured in N2B27-CDM only (control) condition. After 5 treatment days (i.e., D11), immunocytochemical staining for EYA1 and SIX4 exceeded 85% with Noggin (Noggin/SB/F/I) or LDN193189 (LDN/SB/F/I) (Figs. 2H, 2I ). Noggin/SB/F/I and LDN/ SB/F/I were equally effective in inducing the PPE lineage. We then quantified the PPE-like cells still expressing marker for undifferentiated hESCs (OCT3/4; Fig. 2J, left) . LDN/SB/F/I treatment for 5 days significantly reduced OCT3/4 expression from 45.3% with N2B27-CDM-only treatment to 17.3% (Fig. 2J , left) (p < .01). During otocyst stages, p75
NTR is expressed in identifiable domains of otic epithelium, surrounding mesenchyme, and cochleovestibular ganglion. During late embryogenesis, it is found more specifically in the cochleovestibular ganglion [43] . LDN/SB/F/I treatment for 5 days (Fig. 2J , right) significantly increased the rate of p75 NTR expression from 50.1% to 73.3% (p < .001). As noted below, because of these heterogeneities, we subsequently used positive and negative MACS to enrich for PPE-like cells. Figure 2K shows robust immunocytochemical positivity for PPE markers SIX4 (a), EYA1 (a, c), and SIX1 (d) in PPE-like cells after LDN/SB/F/I treatment for 5 days. These PPE-like cells were also positive for SOX2, indicating expression of pro-sensory neuronal progenitors [4, 44] . Finally, RT-PCR analyses revealed that adding FGF2 reduced SOX10 expression (Supporting Information Fig. 1B) , suggesting a PPE rather than a neural crest lineage. Semi-quantitative RT-PCR analyses revealed high levels of expression of p75 NTR (Supporting Information Fig. 1 ).
Stage 2: PPE-Derived ONPs. Positive sorting for p75 NTR and negatively sorting for TRA-1-81 (FACS) or TRA-1-60 (MACS) on D11 enriched the PPE-like cell population (Supporting Information Fig. 1E ). With FACS, 21.5% 6 5.63% of hESC-derived PPE-like cells were TRA-1-81-negative and p75-positive (n 5 3). Similarly, with MACS, 22.3% 6 7.67% of hESC-derived PPE-like cells were TRA-1-60-negative and p75-positive (n 5 3), indicating that these two sorting methods were comparable for achieving desired purification. After purification, cells were differentiated into ONPs (Figs. 1. 3A). Figure 3B demonstrates typical cell morphology after earlyand mid-stage ONP treatment. Short but distinct neurite-like structures are visible. Immunocytochemistry revealed modest expression of ONP markers FOXG1 and GATA3 ( Fig. 3C ) at treatment day 5 and robust expression ( Fig. 3D ) of ONP markers PAX2, PAX8, SOX2, GATA3, and Nestin at treatment day 7 [4, 5, 40, 41, [45] [46] [47] [48] . Quantification of Nestin-positive cells was performed at days 3, 7, and 10 ( Fig. 3E ) to evaluate ONP cell maturity. Nestin was highly expressed after treatment with W/F/I for 7 days (95.7% 6 1.76) compared with the N2B27-CDM-only control (14.7% 6 0.67%). However, even after 10 days of W/F/I treatment, one of SGN markers [9, 45, 49, 50] GATA3 was expressed in only 45.6% 6 4.41% of cells (Fig. 3F) . Thus, while these cells expressed some ONP markers, they had not committed fully to auditory-specific lineages [51] .
Exemplar and summary characterizations of late-stage ONPs are shown in Figure 4 for H1, H7, and H9 hESC lines. To obtain greater incidence of auditory-specific phenotypes, ONPs were treated with SHH, ATRA, EGF, and IGF-1 (S/R/E/F/I) (Figs. 1, 4A). Figure 4B shows GATA3 and FOXG1 immunocytochemistry after S/R/E/F/I treatment for 7 days. ONPs expressed b-III tubulin, a neuron-specific marker [52, 53] (Fig. 4C , first row). Cells also expressed NEUROD1 (a neuroblast marker [54] ) and PAX8, but did not express E-cadherin (ECAD, an otic epithelial marker [40] ) nor SOX10 (data not shown), suggesting that the cells differentiated toward an ONP lineage, rather than an otic epithelial lineage. Over 98% of cells were positive for GATA3 (98.3% 6 1.23% vs. 57.3% 6 3.85% without S/R/E/F/I treatment; p < .05, n 5 10) and over 93 % of cells were positive for PAX8 (93.0% 6 3.05% vs. 59.6% 6 4.26% without S/R/E/F/I treatment; p < .05, n 5 10). S/R/E/F/I treatment did not significantly change the proportions of cells positive for other ONP markers (e.g., FOXG1, Nestin, PAX2, and SOX2; Fig. 4D ). Positivity for SOX2 and Nestin indicates that cells maintained ONP states and did not differentiate into neurons. The reproducibility of our differentiation protocol was evaluated at late-stage ONPs for H1, H7, and H9 hESC lines using immunocytochemical analyses on double-positive cells of PAX8 and GATA3 (Fig. 4E, 4F ). Among those other ONP markers, PAX8, and GATA3 were chosen for this analysis, because S/R/E/ F/I treatment resulted in uniquely greater protein expression in late-stage ONPs (Fig. 4D) . Figure 4F shows comparable result on these three cell lines, which was consistent with other neuronal 926 Placode-Derived SGN-Like Sensory Neurons [27, [55] [56] [57] [58] [59] [60] [61] . Figure 4G summarizes RT-PCR analyses during the sequential step-wise treatments to further characterize the ONPs. W/ F/I treatment combined with S/R/E/F/I treatment at the late-ONP stage resulted in the loss of PAX6 (a marker for neuroectoderm [62] and lens and nasal placode [17] ) and PAX3 (a marker for the trigeminal placode [17] ). PAX2 (a marker for otic and epibranchial placodes [17] ) was stably expressed until late ONP stage. PAX8 (a marker for the otic and epibranchial placodes [17] ) was only weakly expressed in the NNE stage. HOXB1 and HOXB2 were expressed until the NNE stage, whereas HOXA2 and HOXB4 were stably expressed until the late-ONP stage. Finally, SALL4 was strongly expressed until the PPE stage and gradually declined as otic neuronal differentiation progressed.
Stage 3: ONP-Derived SGN-Like Cells. We next sought to determine the capacity of enriched late-stage ONPs to differentiate into mature neurons. We initiated differentiation by removing mitogens (FGF2, EGF, and SHH) and adding factors that support SGN survival, including BDNF [63, 64] , NT-3 [63, 65] , and IGF-1 [66, 67] .
Figure 5B indicates typical morphology of late-stage ONPs treated for 4 weeks with the strategy shown in Figure 4A . Cells displayed bipolar morphology typical of SGNs, with two long neurites extending bilaterally from the soma (white arrows). Figure 5C shows immunocytochemistry of late-stage ONPs differentiated into SGN-like cells for 3-6 weeks using H1, H7, and H9 hESC lines. After treatment for one week, ONPs no longer expressed precursor markers Nestin, SOX2, or SOX10 (data not shown). By 2-4 weeks, cells were positive for peripheral nervous system (PNS) sensory neuron marker peripherin and BRN3A [4, 68] and neuronal marker b-III tubulin and MAP2 [58] . Cells were also positive for TrkB and TrkC receptors, characteristic of human SGNs [63] , and for GluA2-4 and Vglut1, 2, and 3, characteristic of glutamatergic neurons [4, 69] . Cells were no longer positive for Ki67, indicating exit from the cell cycle. These observations indicate that the cells were appropriately differentiated toward the SGN phenotype. However, scattered cells expressed glial markers vimentin and glial fibrillary acidic protein, indicating that cultures were not pure for human SGN characteristics. As illustrated in Figure 5C , virtually all SGN-like cells were positive for vasoactive intestinal polypeptide (VIP) and neuropeptide Y (NPY) and negative for substance P. The cells were also positive for Pejvakin (PJVK) protein [70] and transmembrane protease serine 3 (TMPRSS3) [71] . Figure 5D summarizes the expression of a number of other traits in the SGN-like cells compared with control cells treated only with NIM for 4 weeks. We enumerate the following %-positive cell measures: neurotrophic factors: TrkC-SGN: 98.7 6 1.33, Control: 2.3 6 1.2, p < .001; TrkB-SGN: 95.7 6 3.3, Control: 4.3 6 1.5, p < .001; glutamatergic neuronal markers: Vglut1-SGN: 93.0 6 3.2, Control: 53.0 6 6.1, p < .05; GluA2-4-SGN: 98.0 6 1.2, Control: 75.0 6 4.9, p < .05; PNS sensory markers peripherin-SGN: 82.7 6 2.9, Control: 13.6 6 1.0, p < .01; and Brn3a-SGN: 46.0 6 1.2, Control: 6.3 6 2.0, p < .05).
To assess background staining or staining nonspecific to primary antibodies, samples were treated identically to experimental immunocytochemistry conditions using secondary antibodies with the omission of primary antibody during overnight incubation. Negative results obtained from these 
Physiological Assessments of hESC-Derived SGN-Like Cells
Electrophysiological assays examined the functionality and characteristics of hESC-derived SGN-like cells. By adding highconcentration (50 mM) KCl into solution, calcium imaging with Fura-2 dye (Fig. 6A) showed transient calcium influx upon depolarization, indicating responsive voltage-gated calcium channels. Voltage-clamp recordings [ Fig. 6B(a-b) ] showed transient depolarizing inward currents and subsequent hyperpolarizing outward currents. The current-voltage function of Fig. 6B(c) demonstrates transmembrane conductance and threshold for regenerative current near 220 mV. Whole-cell current clamping also showed that injected depolarizing currents induced action potentials [ Fig. 6B(d)] .
We also obtained measurements from na€ ıve mouse SGNs at P2-P3 for control comparisons. Matching data sets were obtained from three mouse SGNs at P2-P3 with representative response curves shown in Figure 6C(a-d) . For the control SGNs, inward and outward currents were triggered under voltage clamp [ Fig. 6C(a-b) ], but with lower thresholds, larger membrane currents [ Fig. 6C(c) ], and larger spike amplitudes (C-d). Comparisons with these control data are summarized in Figure 6D(a-c) and show that the SGN-like cells had immature response characteristics. First-spike latency for the SGN-like cell was at least twice as great as those from the three control SGNs [ Fig. 6 D(a) ] and spike widths from the hESC-derived cell were longer ( Fig. 6D(a) , p < .0001). Transmembrane currents were an order of magnitude lower for the hESC-derived cell [ Fig. 6D(b) ], which also required larger command voltages for action-potential initiation. Spike amplitudes [ Fig. 6D(c) ] were in all cases smaller than those of controls (p < .0001).
Survival, Migration, and Differentiation of hESC-Derived SGN-Like Cells in Coculture With Auditory Brainstem
We also examined cocultures of hESC-derived late-stage ONPs and rat auditory brainstems containing the CN (Supporting Fig. 2A-2D ). Figure 7 summarizes neurite growth for CN cocultures [ Fig. 7A(a-d, e-h )] or NST coculture [ Fig. 7B(a-c)] . At day 28, transplanted ONPs, originally placed 750 lm from the CN, had migrated toward the CN {white arrow in [ Fig. 7(a) and (e)]}. Figure 7A (c, enlarged in d) shows that some ONPs (expressing peripherin, two white triangles) extended neurites to the surrounding transplanted cells as well as to the CN. Additionally, synaptophysin-positive puncta were observed, suggesting synaptic connections to the ONP aggregates [white arrows, Figure 7A(d, h) . Some transplanted ONPs were positive for BRN3A, suggesting PNS sensory neuronal differentiation in the coculture (Supporting Information Fig. 2F ]. Representative photomicrographs of hESCderived ONPs cocultured with the NST are shown in Fig. 7B . The direction of migration of the ONPs is again shown by white arrows in Figure 7B(a) . Although hESC-derived ONPs extended some neurites to the NST [white arrowhead, Fig. 7B(c) ], they also extended neurites to adjacent brainstem areas (white arrows). There were no significant differences in the numbers of BRN3A-positive and peripherin-positive cells in the cocultures; however, significantly more synaptophysin-positive ONPs were present in cocultures with the CN than with the NST (Fig. 7C; CN: synaptophysin 97.7% 6 0.6% vs. NST: synaptophysin 38.8% 6 3.0%, Student's t test: p < .001). Furthermore, the cells extended more neurites to the CN than to the NST ( Fig. 7D; CN Physiological Assessment of hESC-Derived ONPs in an Organotypic Rat Brainstem Coculture VSD activity (see Supporting Information) was evoked by electric stimulation of the coculture, shown in Figure 7E(a-b) . VSD fluorescence was evident from SGN-like cells located between the IKVAV gel region and brainstem, consistent with aforementioned ONP migration toward the CN. Activity occurred at cell resting states [ Fig. 7F(a) ], consistent with normally hyperpolarized neuronal cells. Twenty-nine regions of interest (ROIs) were identified and plotted [red circles in Fig. 7F(b) ] over the same image, then level-adjusted to reduce background noise (adjusted for visualization purpose only). The mean ROI diameter was 18.5 lm, within human and research-animal SGN diameters (see Supporting Information). Cells were stimulated by 25 lA 100 ls cathodic pulses. Figure 7F(c) shows the electrically-evoked VSD response, obtained by subtracting the resting-state image from that obtained with electrical stimulation; lighter patches aligned with the ROIs indicate evoked depolarization. The null hypothesis that electrically evoked activity caused no VSD intensity change was rejected (p < .05) for 24 of 29 ROIs, with p values shown by color-filled circles in Figure 7F(d) , adjusted for false discovery [72] . Additional information is included in the Supporting Information. (labeled with "NFs/db-cyclic AMP"). Compared with those treated only with N2B27-CDM, GluA2-4, Vglut1 (p < .05), BRN3A, PRPH (p < .01), TrkB, and TrkC (p < .001) expression rates were statistically significantly higher in treated cells, using one-way ANOVA with Tukey's post hoc test: *, p < .05; **, p < .01; ***, p < .001. Abbreviations: BDNF, human brain-derived neurotrophic factor; DAPI, 4 0 ,6-diamidino-2-phenylindole, dihydrochloride; dcyclic AMP, dibutyryl-cyclic AMP GFAP, glial fibrillary acidic protein; NT-3, human neurotrophin-3; IGF-1, insulin-like growth factor 1; NIM, neuronal induction medium; NNE: nonneuronal ectoderm; NPY, neuropeptide Y; ONP: otic neuronal progenitor; PJVK, Pejvakin, PPE: preplacodal ectoderm; PRPH peripherin; TMPRSS3, transmembrane protease serine 3 VIP, vasoactive intestinal polypeptide; Vglut1, Vglut2 and Vglut3, vesicular glutamate transporters. 
DISCUSSION
The ability to generate SGNs from stem cells is required to realize clinical cell-replacement therapies for SNHL. We developed a protocol for reliably and reproducibly deriving purified populations of ONPs and SGN-like cells from hESCs. Chen et al. [5] and Needham et al. [44] previously reported that SGN-like cells can be generated from hESCs. Our work extends these findings by adopting a stepwise protocol closely based upon known developmental stages of the normal ear. We showed that these SGN-like cells express appropriate markers, preferentially extend neurites to the CN rather than to unrelated nuclei, and can generate action potentials, though with immature characteristics. This work advances our understanding of SGN development and developing stem cell therapy for SNHL.
SGNs rely primarily on glutamate to transmit sensory information to the CNS [73] . Our protocol successfully generated glutamatergic SGN-like cells (>98% expressing Glut1 and GluA2-4). Furthermore, nearly all hESC-derived SGNs expressed TrkB and TrkC neurotrophin receptors, which respond to BDNF and NT3, respectively [63] . VIP and NPY were expressed by the SGN-like cells, a characteristic of adult type I or II SGNs [74] . A varying degree of positive staining pattern of substance P on adult human SGNs was previously observed [74] , consistent with our results. Our hESC-derived SGN-like cells expressed PJVK protein, hypothesized to underlie auditory neuropathic hearing losses associated with SGN-specific loss [75] . Recently, this protein was found in human SGNs although expression of this protein is not specific to human SGNs [75] . Furthermore, type-II transmembrane serine protease (TMPRSS3), found in SGN cell bodies [76, 77] , were also expressed by our cells, although once again its presence is not specific to human SGNs.
Importantly, the pattern of transcription factor expression by our cells is similar to the human SGN lineage. A zinc finger transcription factor of the spalt gene family, Sally 4, is expressed in the otic placode [78] . SALL4 was also strongly expressed until the PPE stage, as shown by RT-PCR, suggesting that our hESC-derived ONPs were of otic placode lineage. The Hox genes, coding for a large family of homeobox-containing proteins, display rhombomere-restricted expression patterns and provide early [79] . In turn, the expression of several specific Hox genes is maintained through later stages of circuit formation in distinct, rhombomere-derived neuronal subpopulations of the hindbrain sensory nuclei, including the CN [79] .
Hoxb1 in the hindbrain is required in the facial motor nucleus and the primitive peripheral facial nerve for proper connectivity [80] . Our RT-PCR results indicated that, as differentiation progressed to more mature ONP stages, the treatment induced the expression Placode-Derived SGN-Like Sensory Neurons of HOXA2, HOXB2, and HOXB4 and suppressed HOXB1. As shown by mouse in situ hybridization, Hoxa2 is highly expressed in the ventral portion of the CN (VCN), the first main ascending relay point of SGNs in the auditory system, until postnatal developmental stages [81] . Similarly, Hoxb2 transcripts are found in newborns in the main hindbrain relay nuclei of the auditory circuit, such as the VCN [81] . By contrast, Hoxb1 null mutants exhibit distinct developmental defects on the developing facial nerve originating from the r4 domain of the developing hindbrain [82] . Collectively, these studies indicate that our cells expressed the appropriate Hox genes for the otic lineage.
Our RT-PCR results demonstrating the loss of PAX6 (a marker for the lens and olfactory placode) and PAX3 (a marker for the trigeminal placode) along with persistent expression of PAX2 (a marker for the otic and epibranchial placodes) also indicate that late-stage ONPs had appropriate regional specification. Developmentally, all cranial placodes express Pax genes shortly after PPE induction, with the most rostral (nose and lens) expressing Pax6, the intermediate level (trigeminal) expressing Pax3, and most caudal (ear and epibranchial) expressing Pax2 [42] . This indicates that peripheral neurons derived from late-stage ONPs were guided specifically to otic lineages. Induction of HOXB4 in the late-ONP stage (shown by RT-PCR) also suggests that the late-stage ONPs were appropriately regionally specified (i.e., r6/r7), as Hoxb4 is maintained at the r6/r7 boundary in the mouse embryo [83] . Although hESC-derived ONPs preferentially extended neurites to the CN in our cocultures, some ONPs migrated toward, and appeared to extend neurites to, the NST. Along with our RT-PCR results, this suggests that our ONPs may have included cells of the epibranchial as well as the otic lineage. Nevertheless, both the number of neurites extending to the CN and the number of synaptophysin-positive cells in CN cocultures were significantly higher than those extending to the NST in cultures containing CN and NST targets.
Because there is no single specific ONP molecular marker, we used GATA3 as an indicator to measure ONP maturity. Previous studies indicated that Trans-acting T cell specific transcription factor GATA-3 is a likely regulator of early SGN development. Consistent with this notion, Gata3 was expressed in mouse and chick SGNs but not in vestibular ganglions [46, 84] . Of late-stage ONPs, 98.3% were positive for GATA3 via immunocytochemistry, indicating that the S/R/E treatment effectively increased GATA3 positivity on ONPs. Notably, our hESC-derived late-stage ONPs were also predominantly positive for PAX2, PAX8, SOX2, GATA3, NEUROG1, and NEUROD1, but negative for ECAD. These finding suggest that our ESC-derived late-stage ONPs were in fact ONPs rather than otic vesticle epithelial progenitors.
Interestingly, the rate of BRN3A expression in our hESCderived cells that differentiated to late-stage ONPs was only 46% compared with 82.7% expression of peripherin, another PNS sensory marker. This is consistent with a previous finding using SHH/RA to induce PNS sensory neurons from MSCs [26] . A study using human fetal inner-ear stem cells indicated that only SHH and FGF2 are required to induce BRN3A expression [50] and noted that the combination of IGF-1 and FGF2 appeared to prevent neuronal differentiation by reducing BRN3A expression. Thus, our treatment for generating late-stage ONPs, which contained SHH, ATRA, EGF, and IGF-1, might not have been optimal for generating both ONPs and SGN-like neurons. Our finding that IGF-1 helped to support neuronal differentiation of ONPs is surprising, given previous reports of its effect in rat, mouse, and chick [21, 22, 85] . This emphasizes the importance of studying human system.
Our study used diffusible-ligand treatments to derive SGNlike cells. Such treatments typically have narrow spatial and temporal response windows, which may pose practical problems and compromise across-laboratory reproducibility [27] . An alternative is to generate SGNs through nucleofection of appropriate transfection factors. However, our initial yields using double nucleofection with PAX2 and PAX8 were extremely low (data not shown).
Though not our study's focus, we showed physiological measures consistent with biophysically active neurons using calcium imaging, whole-cell clamping, and VSD. Our whole-cell voltageclamp data suggest that SGN-like cells are immature in terms of temporal properties, currents, and spike amplitudes, possibly linked to sub-adult numbers of ion channels and myelination. Needham et al. (2014) assessed several electrophysiologic properties of their hESC-derived SGN-like cells and found similar abnormalities in slower kinetics, small amplitudes, and smaller ionics currents, consistent with the immature responses we observed. Wider and lower-amplitude action potentials, longer latencies, and smaller ionic currents would predict abnormal auditory brainstem response (ABR) latencies, thresholds, and amplitudes, contrasting with the near-normal ABRs from gerbils treated with hESCs [5] . Clearly, more physiological studies are needed to resolve these differences. Ectopic placement of hESC-derived SGN-like cells [5] may be expected to result in abnormal response growth and altered representation of the exquisite frequency tuning of the cochlea. The popular remedy of cochlear implantation requires a good understanding of electrically-evoked SGN properties and tonotopic representation. Next-generation cochlear prostheses may develop into an adjunct therapy to stem-cell implantation. Thus, better knowledge of acoustically and electrically evoked responses will be needed for translating results to clinical practice.
CONCLUSION
We developed a refined stepwise generation of functional hESCderived SGN-like cells with appropriate expression of most markers found in normal, developing SGNs. Treatment of hESCs with human orthologs of ligands, small molecules, and neurotrophic factors present in chick, Xenopus and murine inner ear embryogenesis generated a relatively pure population of cells phenotypically similar to SGNs that were functionally active and preferentially made synaptic connections to the CN. The ability to selectively control differentiation of hESCs into SGN-like cells is significant for (a) understanding the mechanisms regulating human SGN lineage commitment, (b) development of cell-replacement therapy for profound SNHL, and (c) high-throughput screening for agents that promote SGN survival.
